Nektar Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Nektar Therapeutics (NKTR) has announced its participation in two major healthcare conferences. The company will present at the UBS Global Healthcare Conference in Rancho Palos Verdes on November 13, 2024, at 1:15 p.m. ET, and at the Piper Sandler 36th Annual Healthcare Conference in New York on December 4, 2024, at 1:00 p.m. ET.

Both presentations will be available via webcasts on the company's investor relations website, with replays accessible for 30 days. Interested parties seeking one-on-one meetings with management should contact their respective bank representatives.

News Market Reaction

-1.44%

1 alert

-1.44% News Effect

On the day this news was published, NKTR declined 1.44%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences:

• UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time – webcast link here
• Piper Sandler 36^th Annual Healthcare Conference in New York, NY on Wednesday, December 4, 2024 at 1:00 p.m. Eastern Time / 4:00 p.m. Pacific Time – webcast link here

The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. Replays of the presentations will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective bank representative.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contact:

For Investors:

Vivian Wu
Nektar Therapeutics
628-895-0661

For Media:

Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-upcoming-investor-conferences-302297943.html

SOURCE Nektar Therapeutics

FAQ

When is Nektar Therapeutics (NKTR) presenting at the UBS Global Healthcare Conference 2024?

Nektar Therapeutics will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 1:15 p.m. Eastern Time (10:15 a.m. Pacific Time) in Rancho Palos Verdes, CA.

When is NKTR presenting at the Piper Sandler Healthcare Conference 2024?

Nektar Therapeutics will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 1:00 p.m. Eastern Time in New York, NY.

How long will the NKTR conference presentation replays be available?

Replays of both conference presentations will be available for 30 days on Nektar's investor relations website.

How can investors arrange meetings with NKTR management at these conferences?

Investors interested in one-on-one meetings with Nektar management should contact their respective bank representatives to request a meeting.